{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:38:34Z","timestamp":1790707114897,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The JAVELIN Bladder 100 trial demonstrated improved overall survival (OS) with maintenance avelumab in patients with locally advanced or metastatic urothelial carcinoma UC (la\/mUC) who achieved disease control following first-line platinum-based chemotherapy (1\u00a0L-PBC). However, real-world data on eligibility, utilization, and outcomes of maintenance avelumab therapy remain limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective study included patients with la\/mUC who received 1\u00a0L-PBC. Eligibility for maintenance avelumab therapy was determined based on the best overall response to 1\u00a0L-PBC, with patients who achieved stable disease or a partial or complete response considered eligible. Survival outcomes were analyzed using the Kaplan\u2013Meier method. Multivariate Cox regression analysis was used to identify prognostic factors among patients with la\/mUC who received maintenance avelumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 161 prospective patients, 67.1% were eligible for maintenance avelumab therapy, and 46.3% of eligible patients received the treatment. The median progression-free survival (PFS) following avelumab initiation was 10.2\u00a0months, whereas the median OS was not reached. Prognostic factors associated with PFS included the presence of liver metastases, elevated C-reactive protein (&amp;gt; 1.0\u00a0g\/dL), and administration of more than five cycles of 1\u00a0L-PBC. Adverse events occurred in 60% of patients treated with avelumab, with 16% experiencing grade 3\u20134 adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We emphasize the real-world applicability of maintenance avelumab for Japanese patients with la\/mUC. Maintenance avelumab demonstrated favorable survival outcomes, consistent with clinical trial data. Identifying prognostic factors and optimizing treatment sequencing are essential strategies for improving outcomes in this patient population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyaf008","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T10:11:07Z","timestamp":1737108667000},"page":"522-530","source":"Crossref","is-referenced-by-count":3,"title":["Clinical outcomes and treatment patterns of maintenance avelumab in locally advanced or metastatic urothelial carcinoma: a multicenter collaborative study"],"prefix":"10.1093","volume":"55","author":[{"given":"Yuki","family":"Taneda","sequence":"first","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2599-8183","authenticated-orcid":false,"given":"Fumihiko","family":"Urabe","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Jikei the 3rd Hospital , 4-11-1, Izumihoncho, Komae-shi, Tokyo 201-8601 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Jikei Kashiwa Hospital , 163-1, Kashiwashta, Kashiwa-shi, Chiba 277-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soshi","family":"Kadena","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Jikei the 3rd Hospital , 4-11-1, Izumihoncho, Komae-shi, Tokyo 201-8601 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, JR Tokyo General Hospital , 2-1-13, Yoyogi, Shibuya-ku, Tokyo 151-8528 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Katsushika Medical Center , 6-41-2, Aoto, Katsushika-ku, Tokyo 125-8506 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Kawano","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Tokyo-Kita Medical Center , 4-17-56, Akabanedai, Kita-ku, Tokyo 115-0053 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Takiguchi","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Atsugi Municipal Hospital , 1-16-36, Mizuhiki, Atsugi-shi, Kanagawa 243-8588 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ohtsuka","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Nerima Hikarigaoka Hospital , 2-5-1, Hikarigaoka, Nerima-ku, Tokyo 179-0072 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Nakazono","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Kameda Medical Center , 929, Higashicho, Kamogawa-shi, Chiba 296-8602 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Fuji City General Hospital , 50, Takashimacho, Fuji-shi, Shizuoka 417-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Iwatani","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Jikei Kashiwa Hospital , 163-1, Kashiwashta, Kashiwa-shi, Chiba 277-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotaro","family":"Kayano","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, SUBARU Health Insurance Society Ota Memorial Hospital , 455-1, Ooshimacho, Oota-shi, Gunma 373-8585 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahito","family":"Atsuta","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Jikei Kashiwa Hospital , 163-1, Kashiwashta, Kashiwa-shi, Chiba 277-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Tashiro","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Katsushika Medical Center , 6-41-2, Aoto, Katsushika-ku, Tokyo 125-8506 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Fuji City General Hospital , 50, Takashimacho, Fuji-shi, Shizuoka 417-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6164-4684","authenticated-orcid":false,"given":"Shunsuke","family":"Tsuzuki","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Tokyo-Kita Medical Center , 4-17-56, Akabanedai, Kita-ku, Tokyo 115-0053 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Katsushika Medical Center , 6-41-2, Aoto, Katsushika-ku, Tokyo 125-8506 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Miki","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Jikei Kashiwa Hospital , 163-1, Kashiwashta, Kashiwa-shi, Chiba 277-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5673-1553","authenticated-orcid":false,"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"JIKEI-YAYOI Collaborative Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"2025042804271720000_ref1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025042804271720000_ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.47141471","article-title":"Full analysis from AVENANCE: A real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC)","author":"Barthelemy","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025042804271720000_ref3","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/jjco\/hyad170","article-title":"Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: Response, survival and safety analysis from a multicentre real-world Japanese cohort","volume":"54","author":"Miyake","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"2025042804271720000_ref4","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"2025042804271720000_ref5","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: Results from the JAVELIN bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025042804271720000_ref6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025042804271720000_ref7","doi-asserted-by":"publisher","first-page":"102270","DOI":"10.1016\/j.clgc.2024.102270","article-title":"Real-world treatment patterns and clinical outcomes in patients with locally advanced or metastatic urothelial carcinoma by eligibility for maintenance avelumab, clin genitourinary","volume":"23","author":"Morgans","year":"2025","journal-title":"Cancer"},{"key":"2025042804271720000_ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.8395","article-title":"Uptake of maintenance immunotherapy and changes in upstream treatment selection among patients with urothelial cancer","volume":"6","author":"Mamtani","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025042804271720000_ref9","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1200\/JCO.2023.41.6_suppl.572","article-title":"Real-world treatment patterns sequencing in patients with locally advanced or metastatic urothelial cancer (la\/mUC)in the US","volume":"41","author":"Kearney","journal-title":"J Clin Oncol"},{"key":"2025042804271720000_ref10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1200\/JCO.2023.41.6_suppl.483","article-title":"US real-world first-line (1L) treatment patterns and outcomes for patients with metastatic urothelial carcinoma (mUC) following maintenance avelumab approval","volume":"41","author":"Li","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025042804271720000_ref11","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1200\/JCO.2023.41.16_suppl.4567","article-title":"Real-world response rates and clinical outcomes of patients treated with first-line (1L) platinum-based chemotherapy (PBC) in advanced urothelial cancer (aUC)","volume":"41","author":"Moon","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025042804271720000_ref12","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"2025042804271720000_ref13","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s10147-024-02573-5","article-title":"Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: A multicenter real-world Japanese cohort","volume":"29","author":"Miyake","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"2025042804271720000_ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102212","article-title":"Comparative efficacy of avelumab maintenance therapy versus continued chemotherapy followed by pembrolizumab in metastatic urothelial carcinoma with No progression after 4 cycles of chemotherapy: A retrospective study using propensity score matching","volume":"22","author":"Kobayashi","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"2025042804271720000_ref15","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1200\/JCO.2022.40.16_suppl.4560","article-title":"Long-term outcomes in patients with advanced urothelial carcinoma (UC) who received avelumab first-line (1L) maintenance with or without second-line (2L) treatment: Exploratory analyses from JAVELIN bladder 100","volume":"40","author":"Bellmunt","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025042804271720000_ref16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.eururo.2023.03.030","article-title":"Avelumab first-line maintenance therapy for advanced urothelial carcinoma: Comprehensive clinical subgroup analyses from the JAVELIN bladder 100 phase 3 trial","volume":"84","author":"Grivas","year":"2023","journal-title":"Eur Urol"},{"key":"2025042804271720000_ref17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10147-021-02067-8","article-title":"Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN bladder 100 Japanese subgroup analysis","volume":"27","author":"Tomita","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"2025042804271720000_ref18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO clinical practice guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"2025042804271720000_ref19","doi-asserted-by":"publisher","author":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Bladder Cancer V5.2024.\u00a9 2024","DOI":"10.7196\/samj.9438"},{"key":"2025042804271720000_ref20","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"2025042804271720000_ref21","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1002\/cam4.5165","article-title":"Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma","volume":"12","author":"Matsubara","year":"2023","journal-title":"Cancer Med"},{"key":"2025042804271720000_ref22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.clgc.2021.11.010","article-title":"Enhanced Bellmunt risk score for survival prediction in urothelial carcinoma treated with immunotherapy","volume":"20","author":"Abuhelwa","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"2025042804271720000_ref23","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/cas.14762","article-title":"Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab","volume":"112","author":"Kobayashi","year":"2021","journal-title":"Cancer Sci"},{"key":"2025042804271720000_ref24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s10147-021-02061-0","article-title":"Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: A systematic review and meta-analysis","volume":"27","author":"Yanagisawa","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"2025042804271720000_ref25","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.21873\/anticanres.14921","article-title":"Blood cell count biomarkers predicting efficacy of pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"41","author":"Kadono","year":"2021","journal-title":"Anticancer Res"},{"key":"2025042804271720000_ref26","doi-asserted-by":"publisher","DOI":"10.2144\/fsoa-2023-0049","article-title":"Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy","volume":"9","author":"Dionese","year":"2023","journal-title":"Future Sci OA"},{"key":"2025042804271720000_ref27","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.eururo.2023.08.001","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: Analysis from JAVELIN bladder 100 by duration of first-line chemotherapy and interval before maintenance","volume":"85","author":"Sridhar","year":"2024","journal-title":"Eur Urol"},{"key":"2025042804271720000_ref28","doi-asserted-by":"publisher","first-page":"540.e1","DOI":"10.1016\/j.urolonc.2022.07.008","article-title":"Limited predictive impact of tumor size dynamics on further tumor shrinkage after 4 cycles of first-line chemotherapy in patients with advanced urothelial carcinoma","volume":"40","author":"Hamada","year":"2022","journal-title":"Urol Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/5\/522\/61477036\/hyaf008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/5\/522\/61477036\/hyaf008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T08:27:22Z","timestamp":1745828842000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/5\/522\/7959288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,1,17]]},"published-print":{"date-parts":[[2025,4,26]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf008","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,1,17]]}}}